FEED the BULL

Welcome to Feed the Bull - A home for investment information and interaction.

Tag: nasdaq:bcsi

Sort
E.g., 2013-05-19
E.g., 2013-05-19
Enter a comma separated list of user names.

Thoratec Corporation (NASDAQ:THOR) a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said it will be participating in the Oppenheimer & Co. 22nd Annual Healthcare Conference on Tuesday, December 13.

Blue Coat Systems, Inc. (NASDAQ:BCSI) witnessed volume of 50.61 million shares during last trade however it holds an average trading capacity of 2.43 million shares. BCSI last trade opened at $25.26 reached intraday low of $25.07 and went +43.65% up to close at $25.11.

Blue Coat Systems, Inc. (NASDAQ:BCSI) witnessed volume of 5.62 million shares during last trade however it holds an average trading capacity of 589,651.00 shares. BCSI last trade opened at $19.21 reached intraday low of $17.06 and went +1.12% up to close at $17.10.

Blue Coat Systems, Inc. (NASDAQ:BCSI) announced that Broadband-Testing, an independent network testing facility and consultancy organization for broadband and network infrastructure products, has released a report commissioned by Blue Coat that compares the performance of a Blue Coat MACH5 WAN Optimization appliance with that of a Riverbed Steelhead appliance.

Crown Equity Holdings, Inc. (OTCBB:CRWE) is pleased to announce its joint venture with Communication Expert Corporation.

The cornerstone of Crown Tele Services Inc. strategy is to meet the highest standards when it comes to delivering VoIP (Voice over Internet Protocol) communications solutions specifically designed to meet the business and residential market needs.

Power3 Medical Products, Inc. (OTC.BB:PWRM) delivered four poster presentations at the 2010 International Conference on Alzheimer's Disease (ICAD) in Honolulu, Hawaii. These presentations discussed NuroPro, Power3's diagnostic test, and focused on Power3's Alzheimer's disease blood serum biomarkers, test and clinical validation trials.

Pages

ADVERTISE WITH US